Dietary supplements for aggressive behaviour in people with intellectual disabilities: A randomised controlled crossover trial.
aggressive behaviour
dietary supplements
intellectual disabilities
randomised controlled trial
Journal
Journal of applied research in intellectual disabilities : JARID
ISSN: 1468-3148
Titre abrégé: J Appl Res Intellect Disabil
Pays: England
ID NLM: 9613616
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
22
09
2022
received:
12
05
2022
accepted:
23
09
2022
pubmed:
13
10
2022
medline:
17
12
2022
entrez:
12
10
2022
Statut:
ppublish
Résumé
Aggressive incidents are common in people with intellectual disabilities. Therefore, we aimed to assess whether supplementation of multivitamins, minerals, and omega-3 fatty acids (FA) reduces aggressive incidents. We conducted a randomised, triple blind, placebo controlled, single crossover intervention trial. People with intellectual disabilities or borderline intellectual functioning, between 12 and 40 years of age, and showing aggressive behaviour were included. Participants received either a daily dose of dietary supplements, or placebo. Primary outcome was the number of aggressive incidents, measured using the Modified Overt Aggression Scale (MOAS). there were 113 participants (placebo, n = 56), of whom 24 (placebo, n = 10) participated in the crossover phase of the trial. All 137 trajectories were included in the analyses. There was no significant difference in mean number of aggressive incidents per day between those assigned to supplements and those who received placebo (rate ratio = 0.93: 95% Confidence Interval [CI] = 0.59-1.45). In this pragmatic trial, we did not find significant differences in the outcomes between the supplement and placebo arms. The COVID-19 pandemic started midway through our trial, this may have affected the results.
Sections du résumé
BACKGROUND
BACKGROUND
Aggressive incidents are common in people with intellectual disabilities. Therefore, we aimed to assess whether supplementation of multivitamins, minerals, and omega-3 fatty acids (FA) reduces aggressive incidents.
METHODS
METHODS
We conducted a randomised, triple blind, placebo controlled, single crossover intervention trial. People with intellectual disabilities or borderline intellectual functioning, between 12 and 40 years of age, and showing aggressive behaviour were included. Participants received either a daily dose of dietary supplements, or placebo. Primary outcome was the number of aggressive incidents, measured using the Modified Overt Aggression Scale (MOAS).
RESULTS
RESULTS
there were 113 participants (placebo, n = 56), of whom 24 (placebo, n = 10) participated in the crossover phase of the trial. All 137 trajectories were included in the analyses. There was no significant difference in mean number of aggressive incidents per day between those assigned to supplements and those who received placebo (rate ratio = 0.93: 95% Confidence Interval [CI] = 0.59-1.45).
CONCLUSION
CONCLUSIONS
In this pragmatic trial, we did not find significant differences in the outcomes between the supplement and placebo arms. The COVID-19 pandemic started midway through our trial, this may have affected the results.
Identifiants
pubmed: 36224110
doi: 10.1111/jar.13041
pmc: PMC10092216
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-131Subventions
Organisme : Healthcare insurance Fund, The Netherlands
ID : 3326
Informations de copyright
© 2022 The Authors. Journal of Applied Research in Intellectual Disabilities published by John Wiley & Sons Ltd.
Références
J Appl Res Intellect Disabil. 2014 May;27(3):187-99
pubmed: 24464965
CNS Neurosci Ther. 2020 Jan;26(1):5-13
pubmed: 31490017
J Altern Complement Med. 2000 Feb;6(1):7-17
pubmed: 10706231
Br J Psychiatry. 2002 Jul;181:22-8
pubmed: 12091259
J Autism Dev Disord. 2010 May;40(5):599-609
pubmed: 19941156
J Child Psychol Psychiatry. 2018 Mar;59(3):232-246
pubmed: 28967099
J Neuropsychiatry Clin Neurosci. 1991 Spring;3(2):S22-9
pubmed: 1821217
Int J Dev Disabil. 2020 Oct 5;68(4):578-582
pubmed: 35937180
J Intellect Disabil Res. 2010 Jan 1;54(1):17-25
pubmed: 19627427
Arch Psychiatr Nurs. 2012 Dec;26(6):487-94
pubmed: 23164405
J Child Adolesc Psychopharmacol. 2020 Jun;30(5):280-284
pubmed: 32515992
Neurosci Biobehav Rev. 2007;31(5):752-74
pubmed: 17433442
J Child Psychol Psychiatry. 2016 Sep;57(9):1038-46
pubmed: 27166583
BJPsych Open. 2022 Feb 03;8(2):e42
pubmed: 35109953
Hum Psychopharmacol. 2013 May;28(3):238-47
pubmed: 23625531
J Neurochem. 2006 Sep;98(5):1474-86
pubmed: 16923160
Res Dev Disabil. 2013 Aug;34(8):2407-18
pubmed: 23711630
Nutrients. 2016 Jan 27;8(2):68
pubmed: 26828517
Nutr Rev. 2012 Oct;70(10):594-610
pubmed: 23035806
J Intellect Disabil Res. 2020 Sep 21;:
pubmed: 32954592
J Neuropsychiatry Clin Neurosci. 1991 Spring;3(2):S52-6
pubmed: 1687961
J Nerv Ment Dis. 1988 Sep;176(9):539-46
pubmed: 3418327
Pharmacopsychiatry. 1990 Nov;23(6):249-52
pubmed: 2284325
J Pediatr Psychol. 2020 Aug 1;45(7):720-724
pubmed: 32676670
Br J Nutr. 2016 Jan 28;115(2):361-73
pubmed: 26573368
BMC Pediatr. 2011 Dec 12;11:111
pubmed: 22151477
Public Health Nutr. 2017 Sep;20(13):2289-2299
pubmed: 28625202
Br J Nutr. 2016 Feb 14;115(3):517-26
pubmed: 26628073
Epilepsy Res. 2001 May;45(1-3):43-7; discussion 49-51
pubmed: 11461793
J Nutr Biochem. 2013 May;24(5):725-43
pubmed: 23517914
J Appl Res Intellect Disabil. 2021 Jul;34(4):1156-1165
pubmed: 33783081
J Appl Res Intellect Disabil. 2023 Jan;36(1):122-131
pubmed: 36224110
Aggress Behav. 2010 Mar-Apr;36(2):117-26
pubmed: 20014286
Expert Rev Neurother. 2013 Jan;13(1):49-73
pubmed: 23253391